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Introduction
Coronary heart disease (CHD) is a major
cause of morbidity and mortality in the United
Kingdom, accounting for just under one quar-
ter of all deaths in 1995: 27% among men and
21% among women.1 Although many CHD
deaths occur among elderly people, CHD
accounts for 31% of male and 13% of female
deaths within the 45–64 age group.
Coronary heart disease imposes high social
costs, including impaired quality of life and
reduced economic activity. A large share of
National Health Service (NHS) resources are
also accounted for by CHD.2 One CHD risk
factor is serum cholesterol concentration.
Much attention has been focused on screening
people to identify those with raised cholesterol
concentrations and then trying to lower these
concentrations through diet or medical treat-
ment. This paper is an edited version of a
recent EVective Health Care bulletin, Vol 4, No
1, February 1998, which considers whether
cholesterol screening is worthwhile and exam-
ines the eVectiveness and cost eVectiveness of
the statins and a range of other interventions to
reduce CHD. It aims to provide a summary of
the research evidence which can be used to
establish cost eVective policies.
This topic was covered in a previous issue of
EVective Health Care.3 4 However, since then a
new class of cholesterol lowering drugs—the
statins—has been developed and evaluated.
The expenditure on statin drugs in England
was over £20 million in 1993 and by 1997 had
risen to over £113 million.
The average concentration of blood choles-
terol within a population is an important
determinant of the risk of CHD in the popula-
tion. In countries where the average cholesterol
concentrations of the population are low, CHD
tends to be uncommon. Prospective studies
show that groups of people with lower concen-
trations of cholesterol run less risk of develop-
ing CHD. The association between cholesterol
concentration and future risk of CHD is
graded and continuous: there is no threshold
above which CHD risk begins to increase.
There has been some concern that low
concentrations of blood cholesterol increase
the risk of mortality from causes other than
CHD, including cancer, respiratory disease,
liver disease, and accidental or violent death.
Several studies have now shown that this
mostly, or entirely, is due to the fact that people
with low cholesterol concentrations include a
disproportionate number whose cholesterol
has been reduced by illness—early cancer, res-
piratory disease, gastrointestinal disease, and
alcoholism, among others.5–7 Thus it seems to
be the pre-existing disease which causes both
the low cholesterol and raised mortality.8
DiVerences in mean concentrations of blood
cholesterol between communities or popula-
tions are largely determined by diVerences in
diet. Countries with high dietary saturated fat
intake and a low ratio of polyunsaturated to
saturated fatty acids have high mean choles-
terol concentrations.9 Randomised controlled
trials (RCTs) in institutional settings show that
if components of the diets of individuals are
changed substantially then large changes in
blood cholesterol concentrations can be
achieved.10 Animal experiments and metabolic
ward studies carried out over half a century
show that we should not be surprised by
substantial declines in cholesterol concentra-
tion in someone who is locked in a room and
fed lettuce. The results of trials of externally
regulated dietary intake have, inappropriately,
been taken to be directly translatable into pub-
lic health terms. Understanding what can be
achieved in real life settings by dietary
intervention requires studies of dietary changes
capable of being sustained by ordinary people
leading normal lives.
Although blood cholesterol is an important
risk factor, by itself it is a relatively poor
predictor of who will go on to have a CHD
event. Figure 1 shows the relation between
blood cholesterol and CHD rates in British
men; only 42% of those who will have an event
over 15 years have blood cholesterol over 6.5
mmol/l. This is further illustrated in figure 2
which shows that the distribution of blood
cholesterol in British men aged 40–59 who
subsequently went on to have CHD and those
who did not overlaps considerably.
Other major independent risk factors (smok-
ing, high blood pressure, diabetes, physical
inactivity, and obesity) also exist and should be
considered in defining individual risk of CHD.
Figure 3 shows the importance of considering
risk factors together. Smokers with high blood
pressure have three times the risk of dying of
Quality in Health Care 1998;7:232–239232
Royal Free and
University College
London Medical
School, London, UK
Shah Ebrahim, professor
of clinical epidemiology
Fiona Lampe, research
statistician British
regional heart study
Goya Wannamthee,
senior research fellow
Department of Social
Medicine, University
of Bristol, UK
George Davey-Smith,
professor of clinical
epidemiology
School for Health and
Related Research,
University of SheYeld,
SheYeld, UK
Chris McCabe, lecturer
in health economics
Nick Payne, senior
lecturer in public health
medicine
Mark Pickin, MRC
research fellow
Fiona Sampson,
operational research
analyst
Sue Ward, senior
operational research
analyst
NHS Centre for
Reviews and
Dissemination,
University of York,
York, UK
Trevor A Sheldon,
professor
Correspondence to:
Professor Shah Ebrahim,
Department of Social
Medicine, University of
Bristol, Canynge Hall,
Whiteladies Road, Bristol,
BS8 2PR, UK.
Accepted for publication
8 September 1998
 on 23 January 2006 qhc.bmjjournals.comDownloaded from 
CHD compared with non-smokers with low
blood pressure when both have the same
concentration of blood cholesterol. Risk scor-
ing systems developed from the British Re-
gional Heart Study were no more accurate in
predicting who had coronary heart disease with
blood cholesterol included than without, high-
lighting the importance of these other major
risk factors.11
Detecting raised cholesterol
The main screening test for blood cholesterol is
the measurement of total blood cholesterol in
blood samples obtained by either venepuncture
or finger prick. Cholesterol measurements may
not accurately reflect the true cholesterol con-
centration due to measurement error (bias and
imprecision) and natural biological variation in
cholesterol concentrations within a person.
These sources of error can result in misclassifi-
cation and lead to the incorrect diagnosis and
the possibility of unnecessary treatment.
Measurement error can be the result of bias
(the degree to which a reading systematically
diVers from a gold standard or reference value)
or imprecision (where measurements are sub-
ject to random measurement error). There is
considerable evidence that diVerent laboratory
analysers can give diVerent readings for the
same blood sample.12 For example, a United
Kingdom study found that laboratory equip-
ment systematically overestimated cholesterol
concentrations by over 4% at the cut oV of 7.8
mmol/l.13 This would result in a 50% increase
in the number of people tested subsequently
being recommended for treatment. Bias can be
reduced in laboratory equipment by regular
calibration against a standard, and precision
increased with good equipment and repeat
analyses.
The increasing use of compact measuring
devices such as desk top analysers in general
practitioners’ surgeries and their spread to high
street chemist and health food stores, is of
potential concern. They are less accurate,14 15
making it diYcult to distinguish confidently
between people with raised and normal choles-
terol concentrations,16 and are less amenable to
national initiatives for quality assurance. Stud-
ies of the use of such analysers in general prac-
tice suggest that quality control is a major
problem due to lack of time, poor technique,
and the use of outdated test strips.17 18 Avail-
ability of analysers was associated with a three-
fold increase in cholesterol estimation, al-
though the value of this extra information was
not assessed.19
Even when evaluated in optimal conditions
the performance of some machines has been
inadequate,20 although more recent disposable
devices have achieved reasonable accuracy and
precision.21 Home cholesterol testing kits with
such disposable devices, which have not been
evaluated under the circumstances for which
they are marketed, are unlikely to perform
well.22
In any person the blood cholesterol concen-
tration is not constant over time. This random
biological variation is quite large and results in
considerable misclassification. Estimates of
variation within a person show a coeYcient of
variation for measurements made 1 year apart
of 7% which is large compared with the
coeYcient of variation between people of 15%.
In British men, the implication of this biologi-
cal variation is that 28% of men classified as
Figure 1 Coronary heart disease events and cholesterol
concentration.
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Figure 2 Blood cholesterol in British men aged 40–59 and
coronary heart disease events.
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Figure 3 Mortality from coronary heart disease in British men related to blood cholesterol, diastolic blood pressure, and
smoking.
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having a raised blood cholesterol on a single
testing will have a normal long term blood
cholesterol.23 To reduce misclassification sev-
eral (at least two) measurements should be
made separated by a few weeks, and clinical
decisions should be based on the mean of sev-
eral readings rather than a single measurement.
EFFECT OF SCREENING ON CHOLESTEROL
CONCENTRATIONS
Early enthusiasm in the United States for a
patient centred approach—the “know your
number” campaign—resulted in many people
being screened and given dietary advice. How-
ever, evidence from randomised controlled
trials in the United States and Britain show that
untargeted screening of the general population
coupled with dietary advice have little eVect on
cholesterol concentrations.24–26
OTHER EFFECTS OF SCREENING
Screening—either large scale or oppor-
tunistically—is never entirely without the risk
of harm. Knowledge of the presence of a risk
factor may result in people who previously felt
well thinking that they are sick, as has been
found in hypertension.27 28 Only limited evi-
dence from case studies is available to deter-
mine the potential influence of blood choles-
terol screening on labelling, and showed similar
eVects to those seen in hypertension.29 How-
ever, a trial and a before-after study did not
show any adverse eVects.30 31
Another possible adverse eVect of popula-
tion cholesterol screening is that being in-
formed that one’s cholesterol concentration is
normal may result in adverse lifestyle choices,
so interfering with the general public health
strategies. An Australian study showed that
most (61%) people who had their blood
cholesterol tested by case finding were unwill-
ing to make dietary changes to their fat intakes
on the grounds that their cholesterol concen-
trations were “all right”.32
Cholesterol lowering interventions
Cholesterol concentrations can be lowered by
several types of interventions, diet and drugs
being the most important.
Diet
Changes in individual dietary intake of satu-
rated fats and cholesterol have been studied
extensively (table 1). The eVectiveness of low
fat diets depends critically on how restrictive
they are and the degree of adherence. In
settings where patients’ diets are controlled by
others—such as in metabolic wards—where
adherence to diets is likely to be high, dietary
changes have produced substantial reductions
in blood cholesterol.10 However, studies in the
general population have shown only small
changes in cholesterol.33–36 These studies sug-
gest that the extent of cholesterol reduction
which may be expected from recommending
lipid lowering diets is likely to be very small
(1–5%)35 36 and the eVect on clinical events has
been shown to be disappointing (OR=0.96;
95% CI 0.89 to 1.04).37
The eVects of dietary interventions used
alone after myocardial infarction showed a
greater fall in blood cholesterol than the other
dietary trials,37 probably because the partici-
pants were more motivated to follow strict diets
or lived in institutions where control over diet
was much greater. However, despite the greater
fall in blood cholesterol, the meta-analysis
failed to find any significant reduction in risk of
CHD mortality (RR 0.94; 95% CI 0.84 to
1.06).37
The generally poor performance of some
lipid lowering diets may be partly explained by
the fact that they often substitute complex car-
bohydrates for total fat resulting in a reduction
in both HDL as well as LDL cholesterol. This
reduces total cholesterol but leaves the LDL/
HDL ratio unaVected and so may not reduce
the risk of CHD.10 This highlights the fact that
the real aim should be to lower the risk of CHD
rather than focusing on lowering serum choles-
terol concentrations by themselves.
A systematic review of trials suggested that
garlic may exert a cholesterol lowering eVect
with falls of 0.65 mMol/l (95% CI 0.53 to
0.76) or around 10%.38 However, some of the
trials are severely flawed and, therefore, the
evidence is not reliable. Systematic reviews of
studies evaluating the eVects of consuming
oats39 or psyllium enriched cereals40 show a
small cholesterol lowering eVect of around
2%–5%. A meta-analysis of 38 trials of soy
protein as a substitute for meat protein also
showed a net fall in cholesterol of 0.60 mMol/l
(95% CI 0.35 to 0.85), which was greater in
people with high baseline cholesterol
concentrations.41 However, all these dietary
trials were of relatively short duration and did
not consider clinical end points. Therefore,
there is no evidence that they lower the risk of
CHD.
Drugs
THE STATINS
Over the past few years a new class of more
powerful cholesterol lowering drugs—the stat-
ins (HMG CoA reductase inhibitors)—has
become available. These are able to reduce
LDL cholesterol concentrations by more than
20%. A total of 22 published RCTs of choles-
terol lowering in which clinical outcomes were
recorded were identified for the bulletin and
their results pooled to give an overall estimate
of treatment eVect. Overall, these trials show
that statins reduce the risk of CHD mortality
by around 25% (table 2). The trials which con-
tributed most to the pooled estimates were the
West of Scotland coronary prevention study
Table 1 The eVect of lipid lowering diets in reducing blood
cholesterol concentrations
Blood cholesterol
reduction (mmol/l
(%))
Multiple risk factor intervention trials34 0.14 (2)
Dietary interventions:
General population:
Brunner et al35 0.22 (3)
Tang et al36 0.31 (5)
Including high risk:
Ebrahim and Davey Smith37 0.65 (9)
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(WOSCOPS),42 the Scandinavian Simvastatin
survival study (4S),43 the cholesterol and
recurrent events (CARE) trial,44 and the
recently reported long term intervention with
pravastatin in ischaemic disease (LIPID) trial.45
STATINS COMPARED WITH OTHER CHOLESTEROL
LOWERING DRUGS
The eYcacy (relative risk) of statins in primary
and secondary prevention is summarised for a
range of end points in table 3. For comparative
purposes similar information for fibrates (clofi-
brate and bezafibrate) is also given. Older
drugs—for example, fibrates—are not as eVec-
tive as the newer statins in lowering blood
cholesterol and in reducing rates of CHD
events. The overall eYcacy of older cholesterol
lowering drugs is strongly related to the
baseline level of risk of coronary heart disease.
In high risk populations (>3% annual CHD
death rate), treatment benefits outweigh treat-
ment risk whereas in lower risk populations
there is no place for these older drugs, which
may do harm.46
Further important trial results are awaited
which seem likely to extend the range of
indications for use of statins. The latest trial to
report was the Air Force/Texas coronary
atherosclerosis prevention study of lovastatin in
6605 people (15% women) with no evidence of
coronary heart disease and with average blood
cholesterol concentrations. This trial was
stopped early after finding a 36% reduction in
a combined fatal and non-fatal CHD end point
(study published subsequent to the publication
of the EVective Health Care bulletin) mainly due
to reductions in the rates of revascularisation.47
Pravastatin and simvastatin seem to be
equally eVective in reducing the rates of CHD
events. Interestingly in the AF/TexCAPS trial
neither total mortality nor CHD mortality were
reduced by lovastatin treatment (table 3).
However, less data from large scale trials are
currently available for fluvastatin, atorvastatin,
and cerivastatin and consequently their clinical
eYcacy is not yet established, although they
lower LDL cholesterol to an extent similar to
or greater than other statins.
A meta-analysis of the recently published
data on women from the 4S,48 LIPID study
(preliminary data), CARE study,
AF/TexCAPS,47 and pooled data from several
pravastatin trials49 shows that if both fatal and
non-fatal coronary heart disease events are
considered, women have an on treatment rela-
tive risk of 0.70 (95% CI 0.60 to 0.81), which
is similar to men (no significant interaction
eVect for sexes p=0.45). A report of an
increased risk of breast cancer among treated
women in the CARE study was not confirmed
in the 4S or the LIPID studies. The pooled
results from the four major studies show no
association with breast cancer (RR 1.2; 95% CI
0.66 to 2.13).
Statin treatment in older people is as
eVective as in middle aged adults. The
subgroup analyses of those aged >55 and >65
years within individual trials have reported risk
reductions at least as good as, if not better than,
those among younger participants. Pooling of
these subgroup analyses from the major statin
trials (CARE, 4S, WOSCOPS, AF/TexCAPS
pooled pravastatin trials), shows a relative risk
of combined fatal and non-fatal CHD events of
0.73 (95% CI 0.67 to 0.80) for older people.
People in their late 70s and 80s, although obvi-
ously at increased absolute risk of coronary
heart disease, have not been studied in the
recent statin trials. Treating people in this age
group with statins must, therefore, remain a
matter of clinical judgement until the anti-
hypertensive, lipid lowering after heart attack
trial (ALLHAT), which is examining the
eYcacy of statin treatment in older people,
reports in 2002.
Non-cholesterol lowering alternatives
Cholesterol lowering is only part of the
repertoire of possible eVective interventions to
reduce the risk of CHD and not necessarily the
most important. The risk of CHD can also be
significantly reduced by changes in lifestyle—
for example, stopping smoking, exercise, and
the use of non-cholesterol lowering diets) and
drug treatments—for example, to lower blood
pressure, â blockers after a myocardial infarc-
tion, and aspirin). The eVectiveness of these
Table 2 Summary of major trials of statins
Trial
CHD death
rate* Patient group Treatment
Follow
up (y)
Sex (mean
age or range)
Number
T/C
Baseline
cholesterol
Total: CHD mortality OR
(95% CI)
WOSCOPS
(1995)49
3.8 No CHD evidence
cholesterol:>6.5
mmol/l
Pravastatin 40 mg v
placebo
4.9 Men only
(55)
3302 v
3293
7.03 0.78 (0.60 to 1.00);
0.67 (0.45 to 0.99)
4S trial (1994)50 15.7 Post MI or
angina,cholesterol:
5.5-8.0 mmol/l
Simvastatin 20-40 mg v
placebo
5.4 Men 81%
(60)
2221 v
2223
6.74 0.70 (0.58 to 0.85);
0.58 (0.46 to 0.73)
CARE (1996)51 11.5 Post MI 3-20 mths
cholesterol: <6.2 mmol/l
Pravastatin 40 mg v
placebo
5.0 Men 86%
(59)
2081 v
2078
5.40 0.91 (0.74 to 1.12);
0.80 (0.61 to 1.05)
LIPID (1997)52 13.8 Post MI/ unstable
angina 3-36
mths,cholesterol:
4.0-7.0 mmol/l
Pravastatin 40 mg v
placebo
6.0 M 83%
(31-75)
4512 v
4502
5.60 0.76 (0.67 to 0.86);
0.75 (0.64 to 0.88)
*Control group CHD deaths/1000 patient-years.
CHD=coronary heart disease; MI=myocardial infarction; T=treatment group; C=control group.
Table 3 The relative eYcacy of treatment with drugs that lower cholesterol*
Primary prevention
with statins
Secondary prevention
with statins
Secondary prevention
with fibrates
Total mortality 0.77 (0.60 to 0.99) 0.79 (0.73 to 0.86) 0.97 (0.90 to 1.05)
CHD mortality 0.68 (0.46 to 1.00) 0.74 (0.66 to 0.83) 0.93 (0.85 to 1.01)
Non-fatal MI 0.68 (0.56 to 0.84) 0.70 (0.61 to 0.80) 0.57 (0.28 to 1.11)
Net cholesterol lowering
(%)
20 21 9.5
*Figures are pooled relative risk estimates (95% CI).
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non-cholesterol lowering alternatives is briefly
summarised here and in table 4.
Advice on stopping smoking, given in
primary care settings, has a small but impor-
tant eVect on long term behaviour. Pooled esti-
mates from 188 trials show that around 2%
(95% CI 1% to 3%) of those given personal
advice during one routine consultation stopped
smoking and did not relapse up to 1 year later.50
The use of nicotine gum increases the stop
rates to about 4% (95% CI 2% to 6%). This
will lead to about a 1%–2% overall reduction in
mortality and morbidity. The eVect is much
larger in those who stop, but only a small per-
centage stop with simple advice.
Advice to stop smoking is much more eVec-
tive among those people who have had a myo-
cardial infarction, with up to 36% stopping.51
This results in over a 30% reduction in the risk
of mortality.
Increased intake of oily fish has been shown
to reduce cardiovascular mortality after heart
attack without reducing cholesterol concentra-
tions (RR 0.6 95% CI 0.5 to 0.9). In the DART
trial52 22% of participants did not like oily fish
and consequently were given maxepa supple-
ments. Significant reductions in CHD were
also found in a trial of Mediterranean diet in
people after myocardial infarction, which also
had no eVect on cholesterol concentrations
(RR 0.24 95% CI 0.1 to 0.8).53 54 The most
prominent change in the intervention group
was an increase in consumption of á-linolenic
acid from rape seed margarine (used as the
participants found it difficult to consume high
intakes of olive oil). The striking findings of the
trials of oily fish and Mediterranean diet
certainly require replication, and if substanti-
ated, these diets would have an important role
in reducing mortality after myocardial infarc-
tion. The eVect of these interventions in people
at low risk of CHD is not known.
Lack of physical activity has been shown to
be a strong independent risk factor for death
from CHD.55 It is estimated that a sedentary
lifestyle doubles the risk of mortality from
CHD. However, there are no reliable trials
examining the impact on survival of interven-
tions solely aimed at promoting exercise and
there is considerable debate about the level or
intensity of exercise which confers cardiovas-
cular benefit.56 A recent review found that a
proportion of patients did respond positively to
exercise advice given in a primary care
setting.57 A computer simulation based on the
epidemiological evidence of the association
between exercise and mortality from CHD has
estimated that if the proportion of the popula-
tion undertaking moderate activity were in-
creased by 25%, the number of life-years
gained would be similar to a 2% reduction in
the proportion of smokers.58
Trials of interventions for multiple risk
factors for primary prevention in workplace
settings and primary care show very small and
non-significant eVects on mortality from CHD
(RR 0.96; 95% CI 0.89 to 1.04).34 59 This is
probably due to poor adherence to non-
pharmacological interventions, the use of
drugs which may have had adverse eVects, and
the variable quality of the programmes.
Evidence from trials of rehabilitation after
myocardial infarction are also relevant as many
of these included stopping smoking together
with increases in physical activity. Trials that
attempted to modify several risk factors,
including smoking, and not just increased
physical activity, showed reductions in mor-
tality from CHD (RR 0.63; 95% CI 0.51 to
0.80) and total mortality (RR 0.77; 95% CI
0.64 to 0.94).37 The absolute levels of mortality
from CHD in these trials were of the order of
4% a year in the control group, giving a
number needed to treat of about 13 people for
5 years to avoid one CHD death.
In primary prevention aspirin does not
reduce all cause mortality significantly.60 How-
ever, the participants in both of the large
primary prevention trials were physicians—a
group at very low risk of CHD. Aspirin seems
to reduce mortality among people who have
not yet experienced a myocardial infarction but
who are at high risk of such an event—for
example, unstable angina, stable angina, and
peripheral vascular disease.60 61
Systematic reviews of RCTs show that for
people with high blood pressure anti-
hypertensive medication reduces the risk of
CHD and all cause mortality62 63 including
people after myocardial infarction.65
To help develop the most eYcient policies
for reduction of CHD, the relative cost
eVectiveness of these options was estimated.
The results are given in the next section, and
more details can be obtained from the EVective
Health Care bulletin and associated Health
Technology Assessment Report.
Cost eVectiveness
The cost eVectiveness estimates of various
interventions based on a life table model devel-
oped by the University of SheYeld are shown
in table 5. As the cost per life-year gained is
influenced by the level of risk of the patients
being treated, the values in table 5 were calcu-
lated for a group of patients with the same
average risk of CHD events of 3% a year to aid
comparison.
The costs per life-year gained in primary and
secondary prevention with statins are very
similar to previous estimates based on the
WOSCOPS trial66 and by the 4S investigators67
suggesting that the methods used are valid.
Table 4 Relative treatment eVects for alternative
treatments
Treatment Relative risk (95% CI)
Primary prevention:
Smoking advice50 0.99 (0.98 to 1.0)
Nicotine replacement50 0.98 (0.98 to 0.99)
Aspirin60 0.98(0.78 to 1.18)*
Antihypertensive drugs: 62 63
<60 y 0.79 (0.71 to 0.87)
>60 y 0.75 (0.64 to 0.88)
Statins 0.68 (0.46 to 1.00)
Secondary prevention:
Aspirin60 0.82 (0.76 to 0.88)
â Blockers64 0.78 (0.71 to 0.87)
Statins 0.74 (0.66 to 0.83)
Smoking advice51 0.68(0.57 to 0.79)
Oily fish52 0.65 (0.5 to 0.9)
Mediterranean diet53 54 0.24 (0.1 to 0.8)
*Not significant eVect of treatment.
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The final column in table 5 shows the net
cost per life-year gained which takes into
account potential savings due to avoiding
CHD events and associated costs of treatment
and admissions to hospital. For example,
analyses of the 4S trial data showed that hospi-
tal costs among the simvastatin treated group
were 32% lower than the placebo group,68 and
that almost 90% of the drug costs were oV-set
by savings in hospital admissions.69 However,
because the rates of revascularisation in the
United Kingdom are lower than in Scandinavia
(where the trial was carried out), the savings
are unlikely to be as great. However, more
eVective treatment of people at high risk of
CHD events may reduce pressure for increas-
ing the rates of revascularisation.
Because the baseline level of risk of CHD has
a major impact on the absolute eVect or impact
of interventions it should be taken into account
when deciding who should receive which treat-
ment. This is illustrated in figure 4 which
shows how the cost of achieving an extra year of
life increase as people with lower initial risk of
CHD are treated. A recent economic evalua-
tion of lipid lowering in primary care in
patients with moderately increased risk
doubted whether drug treatment as primary
prevention is cost eVective.70
The data in table 5 provide comparable cost
eVectiveness estimates for a range of interven-
tions. It can be seen that several other
interventions are more cost eVective than stat-
ins. Interventions that stop smoking have also
been shown to be highly cost eVective. The
costs per life saved are low and have been esti-
mated to be about £500 per life-year gained.71
The additional cost per life-year gained of brief
counselling or the use of nicotine substitutes—
for example, gum—over and above brief
advice, is about £2500 if costs to smokers as
well as the NHS are taken into account.
If more people at increased risk of CHD
were appropriately treated with aspirin and
antihypertensive drugs, helped to stop smok-
ing, and changed their diet, then many (possi-
bly over half) would have their risk of CHD
suYciently reduced to make statin treatment
unnecessary or relatively cost ineVective.72
The net cost per life-year gained with statins
of around £7 000 (for patients with an annual
risk of a CHD event of about 3%) compares
favourably with several other interventions
currently provided by the NHS, including
those in the management of coronary heart
disease. If a patient is still at suYciently high
risk after using other more cost eVective
options, the use of a statin may be appropriate.
If the diVerent statins are equally eYcacious
and safe then the use of the drugs with lowest
cost per percentage reduction in cholesterol
would seem to be preferable.
Implications
Universal cholesterol screening is unlikely to be
cost eVective because treatment to reduce risk
factors is most cost eVective when targeted at
people who are at high risk of CHD events and
most people who are at high risk will have a
combination of easily detectable risk factors—
for example, smoking, high blood pressure, or
physical inactivity. The concentration of chol-
esterol by itself is generally too poor a predictor
of CHD. Finally, cholesterol lowering confers
considerable benefits to people who are at high
risk of CHD even if they have average concen-
trations of cholesterol by British standards.
By focusing too heavily on concentrations of
cholesterol it is likely that a considerable
proportion of those at high risk would be
missed and that treatment could be oVered to
people who are not at high risk but who have
Table 5 Costs per year of life gained (£PLYG) for a range of diVerent interventions in patients with an absolute baseline
risk of CHD events of 3%/y in primary prevention or secondary prevention after myocardial infarction
£PYLG, gross (95% CI) £PYLG, net
Drug interventions:
Statins:
Simvastatin 27 mg/day (1.37p/day) £8240 (£6220to11280) £7240
Antihypertensive drugs (bendrofluazide 2.5 mg, 0.1p/day):*
Middle aged £70 (£40 to 130) £580 (saved)
Elderly† £45 (£30 to 180) £870 (saved)
Antihypertensive drugs (combined regimen of bendrofluazide, atenolol, enalapril, 53 p/day):*
Middle aged £1501 (£940 to 3050) £860
Aspirin (300 mg/day, ‡0.5 p/day)* £50 (£30 to 320) £407 (saved)
Aspirin (150 mg) + dipyridamole (400 mg, 24p/day)* £2800 (£1500to17080) £2340
â Blockers (atenolol 50 mg, 3.8 p/day)* £230 (£170 to 410) £130
Dietary interventions:*
Fish diet, advice only (£41/year) £560 (£330 to 2220) £610
Fish diet + 20 mg maxepa/week (£57/year) £780 (£460 to 3110) £830
Mediterranean diet (£52/year) £290 (£200 to 1980) £180
CHD=coronary heart disease; PLYG=per life-year gained. Figures are £ (1998) PLYG with discounting of costs and benefits at 6%
for patients with an absolute baseline risk of CHD events of 3%/y. Net costs take into account projected savings from reduced
admissions and treatment for clinical events avoided.
*No data on revascularisation procedures avoided by treatment, hence potential savings are underestimated.
†CHD event rate for elderly people was derived from trials and was equivalent to 4.5%/y.
‡ Aspirin dose used in postmyocardial infarction trials was 1.2 g/day but current practice would favour a lower dose.
Figure 4 Cost per life-year gained with statins by initial
risk of coronary heart disease.
20
15
10
0
Coronary heart disease event rate (%)
£ 
(t
h
o
u
sa
n
d
s)
 p
er
 li
fe
-y
ea
r 
g
ai
n
ed
3.0
5
1.51.0 4.5 10.0
Cholesterol and coronary heart disease: screening and treatment 237
 on 23 January 2006 qhc.bmjjournals.comDownloaded from 
moderately increased cholesterol concentra-
tions. It is probably only worth measuring
cholesterol in patients who have either a strong
family history of CHD or other easily identifi-
able risk factors, and to monitor serum lipid
changes in patients on cholesterol lowering
treatments or diets.
In people with cardiovascular disease or
diabetes, who are at high risk of CHD events,
the evidence for the eVectiveness of statins is
strong. However, the cost per life-year gained is
high compared with some other drug treat-
ments and lifestyle changes, which may pro-
duce net savings of healthcare resources. It is of
concern, therefore, that people who might
benefit from treatment after myocardial infarc-
tion are not being treated. A recent survey of
hospitals in the United Kingdom showed that
secondary prevention in patients at high risk of
mortality from CHD because of a history of a
coronary artery bypass grafting, percutaneous
transluminal coronary angioplasty, or acute
myocardial infarction was highly variable and
that many risk factors remained unmanaged.73
This shows the considerable potential for the
cost eVective reduction of risks in patients with
established coronary disease. A first priority
must be to ensure that appropriately targeted
interventions that are clearly more cost eVec-
tive are used in practice. Cost eVective consid-
erations mean that statins should only be used
for people who are at high risk after using
other, more cost eVective, interventions (table
5).
The level of risk of CHD above which it is
decided that the use of statins is suYciently
cost eVective as to justify routine use, however,
is not a technical issue but a question of policy.
This depends on the valuation of treatment
benefits, the resources available, and the cost
eVectiveness of alternative uses of those
resources. Various scoring systems are available
to help estimate a person’s overall risk of
CHD—such as the SheYeld tables.74 75 How-
ever, they all have weakness and they do not
take into account the increased risk associated
with certain ethnic groups—for example, south
Asians—or low socioeconomic status. Research
is needed to develop and evaluate an easy to
use and more accurate risk formula which can
be used in primary care not only to calculate
risk but to assess the likely eVect of modifying
risk factors for each patient. This will also make
it possible for patients to make informed deci-
sions on the basis of individual and valid
estimates of their risk and trade oVs with ben-
efits of diVerent interventions.76
This paper is based on work funded in part by the NHS Health
Technology Assessment programme.
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